Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 15/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960124 | 0.92 | KMT2A (0.52) | SSTR5KCNH2KMT2AMCHR1CCR3 | |
| SCHEMBL2952216 | 0.90 | MCHR1 (0.54) | SSTR5MCHR1 | |
| SCHEMBL2953836 | 0.90 | SSTR5 (0.60) | SSTR5KCNH2KMT2AMCHR1CCR3 | |
| SCHEMBL2964855 | 0.88 | MCHR1 (0.57) | SSTR5KCNH2KMT2AMCHR1CCR3 | |
| SCHEMBL2964753 | 0.85 | SSTR5 (0.52) | SSTR5KCNH2KMT2AMCHR1CCR3 | |
| SCHEMBL2960441 | 0.84 | SSTR5 (0.59) | SSTR5KCNH2KMT2AMCHR1CCR3 | |
| SCHEMBL2957931 | 0.82 | MCHR1 (0.57) | SSTR5MCHR1 | |
| SCHEMBL2963841 | 0.82 | SSTR5 (0.60) | SSTR5KCNH2KMT2AMCHR1CCR3 | |
| SCHEMBL2960465 | 0.81 | SSTR5 (0.55) | SSTR5KCNH2KMT2AMCHR1SSTR1 | |
| SCHEMBL2963370 | 0.80 | MCHR1 (0.59) | SSTR5KCNH2KMT2AMCHR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885KCNH2 1054/4885KMT2A 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.